This finding is of importance, as previous studies suggested that RAASi medication may contribute to COVID-19 mortality [2, 17–19], a hypothesis based on (1) the relatively high incidence of hypertension among SARS-CoV-2-infected patients [2]; (2) the findings of preclinical investigation showing that some RAASi medications result in increases in circulating ACE2 levels in animal models [21, 22]; and (3) the observation that ACE2 is critical for the binding and entry of SARS-CoV-2 to the cells [8, 9]. Here, ACE2 is linked to hypertensive disorder.